Innate immunity and cell death in alcoholic liver disease: Role of cytochrome P4502E1

Redox Biology

Volumn 2, Issue 1, 2014, Pages 929-935

  Barnes, Mark A ^a,b   Roychowdhury, Sanjoy ^b   Nagy, Laura E ^a,b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Alcoholic liver disease; Cell death; Chemokines; Innate immunity; Necroptosis

Indexed keywords

ALCOHOL; CYTOCHROME P450 2E1;

ALCOHOL LIVER DISEASE; ANIMAL; CELL DEATH; ENZYMOLOGY; HUMAN; IMMUNOLOGY; INNATE IMMUNITY; METABOLISM; PATHOLOGY;

ANIMALS; CELL DEATH; CYTOCHROME P-450 CYP2E1; ETHANOL; HUMANS; IMMUNITY, INNATE; LIVER DISEASES, ALCOHOLIC;

EID: 84905841707     PISSN: 22132317     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.redox.2014.07.007     Document Type: Review

References (50)

1. Tome S., Lucey M.R. Review article: current management of alcoholic liver disease. Alimentary Pharmacology & Therapeutics 2004, 19:707-714. http://www.ncbi.nlm.nih.gov/pubmed/15043511, 10.1016/j.redox.2014.07.007.
2. Gramenzi A., Caputo F., Biselli M., Kuria F., Loggi E., Andreone P., Bernardi M. Review article: alcoholic liver disease-pathophysiological aspects and risk factors. Alimentary Pharmacology & Therapeutics 2006, 24:1151-1161. http://www.ncbi.nlm.nih.gov/pubmed/17014574, 10.1016/j.redox.2014.07.007.
3. Paula H., Asrani S.K., Boetticher N.C., Pedersen R., Shah V.H., Kim W.R. Alcoholic liver disease-related mortality in the United States: 1980-2003. American Journal of Gastroenterology 2010, 105:1782-1787. http://www.ncbi.nlm.nih.gov/pubmed/20179691, 10.1016/j.redox.2014.07.007.
4. Altamirano J., Bataller R. Alcoholic liver disease: pathogenesis and new targets for therapy. Nature Reviews. Gastroenterology & Hepatology 2011, 8:491-501. http://www.ncbi.nlm.nih.gov/pubmed/21826088, 10.1016/j.redox.2014.07.007.
5. Maher J.J. Exploring alcohol's effects on liver function. Alcohol Health and Research World 1997, 21:5-12. http://www.ncbi.nlm.nih.gov/pubmed/15706758.
6. Thakur V., McMullen M.R., Pritchard M.T., Nagy L.E. Regulation of macrophage activation in alcoholic liver disease. Journal of Gastroenterology and Hepatology 2007, 22(Suppl. 1):S53-S56. http://www.ncbi.nlm.nih.gov/pubmed/17567466, 10.1016/j.redox.2014.07.007.
7. Lieber C.S. Microsomal ethanol-oxidizing system (MEOS): the first 30 years (1968-1998)-a review. Alcoholism, Clinical and Experimental Research 1999, 23:991-1007. http://www.ncbi.nlm.nih.gov/pubmed/10397283, 10.1016/j.redox.2014.07.007.
8. Lieber C.S. ALCOHOL: its metabolism and interaction with nutrients. Annual Review of Nutrition 2000, 20:395-430. http://www.ncbi.nlm.nih.gov/pubmed/10940340, 10.1016/j.redox.2014.07.007.
9. Wu D., Cederbaum A.I. Alcohol, oxidative stress, and free radical damage. Alcohol Research & Health: The Journal of the National Institute on Alcohol Abuse and Alcoholism 2003, 27:277-284. http://www.ncbi.nlm.nih.gov/pubmed/15540798.
10. Elmore S. Apoptosis: a review of programmed cell death. Toxicologic Pathology 2007, 35:495-516. http://www.ncbi.nlm.nih.gov/pubmed/17562483, 10.1016/j.redox.2014.07.007.
11. Malhi H., Guicciardi M.E., Gores G.J. Hepatocyte death: a clear and present danger. Physiological Reviews 2010, 90:1165-1194. http://www.ncbi.nlm.nih.gov/pubmed/20664081, 10.1016/j.redox.2014.07.007.
12. Vandenabeele P., Galluzzi L., Vanden Berghe T., Kroemer G. Molecular mechanisms of necroptosis: an ordered cellular explosion. Nature Reviews. Molecular Cell Biology 2010, 11:700-714. http://www.ncbi.nlm.nih.gov/pubmed/20823910, 10.1016/j.redox.2014.07.007.
13. Roychowdhury S., McMullen M.R., Pisano S.G., Liu X., Nagy L.E. Absence of receptor interacting protein kinase 3 prevents ethanol-induced liver injury. Hepatology 2013, 57:1773-1783. http://www.ncbi.nlm.nih.gov/pubmed/23319235, 10.1016/j.redox.2014.07.007.
14. He S., Wang L., Miao L., Wang T., Du F., Zhao L., Wang X. Receptor interacting protein kinase-3 determines cellular necrotic response to TNF-alpha. Cell 2009, 137:1100-1111. http://www.ncbi.nlm.nih.gov/pubmed/19524512, 10.1016/j.redox.2014.07.007.
15. Zhang D.W., Shao J., Lin J., Zhang N., Lu B.J., Lin S.C., Dong M.Q., et al. RIP3, an energy metabolism regulator that switches TNF-induced cell death from apoptosis to necrosis. Science 2009, 325:332-336. http://www.ncbi.nlm.nih.gov/pubmed/19498109, 10.1016/j.redox.2014.07.007.
16. Upton J.W., Kaiser W.J., Mocarski E.S. Virus inhibition of RIP3-dependent necrosis. Cell Host & Microbe 2010, 7:302-313. http://www.ncbi.nlm.nih.gov/pubmed/20413098, 10.1016/j.redox.2014.07.007.
17. Gao B., Jeong W.-I., Tian Z. Liver: an organ with predominant innate immunity. Hepatology 2008, 47:729-736. http://www.ncbi.nlm.nih.gov/pubmed/18167066, 10.1016/j.redox.2014.07.007.
18. Wang H.J., Gao B., Zakhari S., Nagy L.E. Inflammation in alcoholic Liver disease. Annual Review of Nutrition 2012, 32:343-368. http://www.ncbi.nlm.nih.gov/pubmed/22524187, 10.1016/j.redox.2014.07.007.
19. An L., Wang X., Cederbaum A.I. Cytokines in alcoholic liver disease. Archives of Toxicology 2012, 86:1337-1348. http://www.ncbi.nlm.nih.gov/pubmed/22367091, 10.1016/j.redox.2014.07.007.
20. Yin M., Wheeler M.D., Kono H., Bradford B.U., Gallucci R.M., Luster M.I., Thurman R.G. Essential role of tumor necrosis factor alpha in alcohol-induced liver injury in mice. Gastroenterology 1999, 117:942-952. http://www.ncbi.nlm.nih.gov/pubmed/10500078, 10.1016/j.redox.2014.07.007.
21. McClain C.J., Cohen D.A. Increased tumor necrosis factor production by monocytes in alcoholic hepatitis. Hepatology 1989, 9:349-351. http://www.ncbi.nlm.nih.gov/pubmed/2920991, 10.1016/j.redox.2014.07.007.
22. Tilg H., Wilmer A., Vogel W., Herold M., Nölchen B., Judmaier G., Huber C. Serum levels of cytokines in chronic liver diseases. Gastroenterology 1992, 103:264-274. http://www.ncbi.nlm.nih.gov/pubmed/1612333.
23. National Institute on Alcohol Abuse and Alcoholism, The Cleveland Clinic, University of Massachusettes WUoL, Efficacy Study of Anakinra, pentoxifylline, and zinc compared to Methylprenisolone in severe acute alcoholic hepatitis, Clinical Trials.gov [Internet], National Institutes of Health (NIAAA), 2013 [cited 2014 Jun 24].
24. Cohen J.I., Roychowdhury S., McMullen M.R., Stavitsky A.B., Nagy L.E. Complement and alcoholic liver disease: role of C1q in the pathogenesis of ethanol-induced liver injury in mice. Gastroenterology 2010, 139:664-674. http://www.ncbi.nlm.nih.gov/pubmed/20416309, 10.1016/j.redox.2014.07.007.
25. Pritchard M.T., McMullen M.R., Stavitsky A.B., Cohen J.I., Lin F., Medof M.E., Nagy L.E. Differential contributions of C3, C5, and decay-accelerating factor to ethanol-induced fatty liver in mice. Gastroenterology 2007, 132:1117-1126. http://www.ncbi.nlm.nih.gov/pubmed/17383432, 10.1016/j.redox.2014.07.007.
26. Le Y., Zhou Y., Iribarren P., Wang J. Chemokines and chemokine receptors: their manifold roles in homeostasis and disease. Cellular & Molecular Immunology 2004, 1:95-104. http://www.ncbi.nlm.nih.gov/pubmed/16212895.
27. Mandrekar P., Ambade A., Lim A., Szabo G., Catalano D. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice. Hepatology 2011, 54:2185-2197. http://www.ncbi.nlm.nih.gov/pubmed/21826694, 10.1016/j.redox.2014.07.007.
28. Bloom B.R., Bennett B. Mechanism of a reaction in vitro associated with delayed-type hypersensitivity. Science 1966, 153:80-82. http://www.ncbi.nlm.nih.gov/pubmed/5938421, 10.1016/j.redox.2014.07.007.
29. David J.R. Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proceedings of the National Academy of Sciences of the United States of America 1966, 56:72-77. http://www.ncbi.nlm.nih.gov/pubmed/5229858, 10.1016/j.redox.2014.07.007.
30. Isaacs A., Lindenmann J. Virus interference. I. The interferon. Proceedings of the Royal Society B: Biological Sciences 1957, 147:258-267. 10.1016/j.redox.2014.07.007.
31. Calandra T., Roger T. Macrophage migration inhibitory factor: a regulator of innate immunity. Nature Reviews. Immunology 2003, 3:791-800. http://www.ncbi.nlm.nih.gov/pubmed/14502271, 10.1016/j.redox.2014.07.007.
32. Kumagi T., Akbar F., Horiike N., Onji M. Increased serum levels of macrophage migration inhibitory factor in alcoholic liver diseases and their expression in liver tissues. Clinical Biochemistry 2001, 34:189-193. http://www.ncbi.nlm.nih.gov/pubmed/11408016, 10.1016/j.redox.2014.07.007.
33. Bernhagen J., Calandra T., Mitchell R.A., Martin S.B., Tracey K.J., Voelter W., Manogue K.R., et al. MIF is a pituitary-derived cytokine that potentiates lethal endotoxaemia. Nature 1993, 365:756-759. http://www.ncbi.nlm.nih.gov/pubmed/8413654, 10.1016/j.redox.2014.07.007.
34. Korhonen R., Moilanen E. Mitogen-activated protein kinase phosphatase 1 as an inflammatory factor and drug target. Basic & Clinical Pharmacology & Toxicology 2014, 114:24-36. http://www.ncbi.nlm.nih.gov/pubmed/24112275, 10.1016/j.redox.2014.07.007.
35. Onodera S., Nishihira J., Iwabuchi K., Koyama Y., Yoshida K., Tanaka S., Minami A. Macrophage migration inhibitory factor up-regulates matrix metalloproteinase-9 and -13 in rat osteoblasts: relevance to intracellular signaling pathways. Journal of Biological Chemistry 2002, 277:7865-7874. http://www.ncbi.nlm.nih.gov/pubmed/11751895, 10.1016/j.redox.2014.07.007.
36. Gregory J.L., Hall P., Leech M., Morand E.F., Hickey M.J. Independent roles of macrophage migration inhibitory factor and endogenous, but not exogenous glucocorticoids in regulating leukocyte trafficking. Microcirculation 2009, 16:735-748. http://www.ncbi.nlm.nih.gov/pubmed/19905972, 10.1016/j.redox.2014.07.007.
37. Barnes M.A., McMullen M.R., Roychowdhury S., Pisano S.G., Liu X., Stavitsky A.B., Bucala R., et al. Macrophage migration inhibitory factor contributes to ethanol-induced liver injury by mediating cell injury, steatohepatitis, and steatosis. Hepatology 2013, 57:1980-1991. http://www.ncbi.nlm.nih.gov/pubmed/23174952, 10.1016/j.redox.2014.07.007.
38. Bandres E., Bitarte N., Arias F., Agorreta J., Fortes P., Agirre X., Zarate R., et al. microRNA-451 regulates macrophage migration inhibitory factor production and proliferation of gastrointestinal cancer cells. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2009, 15:2281-2290. http://www.ncbi.nlm.nih.gov/pubmed/19318487, 10.1016/j.redox.2014.07.007.
39. Merk M., Baugh J., Zierow S., Leng L., Pal U., Lee S.J., Ebert A.D., et al. The Golgi-associated protein p115 mediates the secretion of macrophage migration inhibitory factor. Journal of Immunology 2009, 182:6896-6906. http://www.ncbi.nlm.nih.gov/pubmed/19454686, 10.1016/j.redox.2014.07.007.
40. Al-Abed Y., Dabideen D., Aljabari B., Valster A., Messmer D., Ochani M., Tanovic M., et al. ISO-1 Binding to the tautomerase active site of MIF inhibits its pro-inflammatory activity and increases survival in severe sepsis. Journal of Biological Chemistry 2005, 280:36541-36544. http://www.ncbi.nlm.nih.gov/pubmed/16115897, 10.1016/j.redox.2014.07.007.
41. Kubes P., Mehal W.Z. Sterile inflammation in the liver. Gastroenterology 2012, 143:1158-1172. http://www.ncbi.nlm.nih.gov/pubmed/22982943, 10.1016/j.redox.2014.07.007.
42. Borghese F., Clanchy F.I. CD74: an emerging opportunity as a therapeutic target in cancer and autoimmune disease. Expert Opinion on Therapeutic Targets 2011, 15:237-251. http://www.ncbi.nlm.nih.gov/pubmed/21208136, 10.1016/j.redox.2014.07.007.
43. Lue H., Dewor M., Leng L., Bucala R., Bernhagen J. Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74. Cellular Signalling 2011, 23:135-144. http://www.ncbi.nlm.nih.gov/pubmed/20807568, 10.1016/j.redox.2014.07.007.
44. Schwartz V., Krüttgen A., Weis J., Weber C., Ostendorf T., Lue H., Bernhagen J. Role for CD74 and CXCR4 in clathrin-dependent endocytosis of the cytokine MIF. European Journal of Cell Biology 2012, 91:435-449. http://www.ncbi.nlm.nih.gov/pubmed/22014447, 10.1016/j.redox.2014.07.007.
45. Kleemann R., Hausser A., Geiger G., Mischke R., Burger-Kentischer A., Flieger O., Johannes F.J., et al. Intracellular action of the cytokine MIF to modulate AP-1 activity and the cell cycle through Jab1. Nature 2000, 408:211-216. http://www.ncbi.nlm.nih.gov/pubmed/11089976, 10.1016/j.redox.2014.07.007.
46. Grieb G., Merk M., Bernhagen J., Bucala R. Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News & Perspectives 2010, 23:257-264. http://www.ncbi.nlm.nih.gov/pubmed/20520854, 10.1016/j.redox.2014.07.007.
47. Bernhagen J., Krohn R., Lue H., Gregory J.L., Zernecke A., Koenen R.R., Dewor M., et al. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nature Medicine 2007, 13:587-596. http://www.ncbi.nlm.nih.gov/pubmed/17435771, 10.1016/j.redox.2014.07.007.
48. Zhang Y., Talwar A., Tsang D., Bruchfeld A., Sadoughi A., Hu M., Omonuwa K., et al. Macrophage migration inhibitory factor mediates hypoxia-induced pulmonary hypertension. Molecular Medicine 2012, 18:215-223. http://www.ncbi.nlm.nih.gov/pubmed/22113497, 10.1016/j.redox.2014.07.007.
49. Arteel G.E., Iimuro Y., Yin M., Raleigh J.A., Thurman R.G. Chronic enteral ethanol treatment causes hypoxia in rat liver tissue in vivo. Hepatology 1997, 25:920-926. http://www.ncbi.nlm.nih.gov/pubmed/9096598, 10.1016/j.redox.2014.07.007.
50. Liu A., Fang H., Dirsch O., Jin H., Dahmen U. Early release of macrophage migration inhibitory factor after liver ischemia and reperfusion injury in rats. Cytokine 2012, 57:150-157. http://www.ncbi.nlm.nih.gov/pubmed/22136975, 10.1016/j.redox.2014.07.007.